KemPharm (United States)

Recent papers from KemPharm (United States)

1. Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral DonepezilJournal of Alzheimer s Disease · 2022
2. Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology · 2022
3. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidateCurrent Medical Research and Opinion · 2022
4. Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor DevelopmentMolecules · 2022
5. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology · 2021
6. Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug UsersPain Medicine · 2019
7. Characterizing Abuse Progression of Immediate-Release Hydrocodone Combination ProductsJournal of Drug Issues · 2018
8. Patterns of abuse and routes of administration for immediate‐release hydrocodone combination productsPharmacoepidemiology and Drug Safety · 2017
9. Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention TrialClinical Cardiology · 2017
10. Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assaultDrug Testing and Analysis · 2010